CeCaVa GmbH & Co. KG

The biotechnology company CeCaVa was founded 2018 in Tübingen with the mission to develop personalized immune-oncology therapies for the treatment of cancer. The technology is based on the genetic analysis of tumors in order to identify for each patient the individual tumor-specific mutations. From these mutations tumor-specific antigens (neoantigens) can be derived and selected to manufacture personalized cancer vaccines. With these vaccines we aim to educate and activate the immune system to recognize and efficiently fight tumor cells carrying such neoantigens on their surface.